<p>ImmunoPrecise Antibodies（納斯達克：IPA - 獲取免費報告）可能會在 2025 年 9 月 15 日星期一市場開盤前公佈其 2026 年第一季度的業績。分析師預計該公司將宣佈每股收益為（$0.04），季度收入為 590 萬美元。投資者可以訪問該公司即將發佈的 2026 年第一季度財報頁面，以獲取關於定於 2025 年 9 月 15 日東部時間上午 10:30 的電話會議的最新詳情。</p>
<ul>
<li>3 只個人護理股票，似乎是良好的收益投資機會</li>
</ul>
<p>ImmunoPrecise Antibodies（納斯達克：IPA - 獲取免費報告）上一次公佈其財報是在 7 月 29 日星期二。該公司報告季度每股收益（EPS）為（$0.04），低於市場共識預期的（$0.02）$0.02。該季度的收入為 506 萬美元，而市場共識預期為 789 萬美元。ImmunoPrecise Antibodies 的淨利潤率為-122.10%，股本回報率為-40.62%。分析師平均預計 ImmunoPrecise Antibodies 在當前財年將發佈$0 的每股收益，並在下一個財年也將發佈$0 的每股收益。</p>
<h2>ImmunoPrecise Antibodies 股價上漲 8.5%</h2>
<p>IPA 週一開盤價為$2.10。該公司的流動比率為 2.08，速動比率為 1.85，債務與股本比率為 0.49。該公司的市值為 9668 萬美元，市盈率為-3.08，貝塔值為 0.53。ImmunoPrecise Antibodies 的 12 個月最低價為$0.27，最高價為$3.25。該股票的 50 日移動平均價格為$1.98，200 日移動平均價格為$1.03。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>MarketBeat 週報 – 07/31 - 08/04</li>
</ul>
<p>另外，華爾街 Zen 在 8 月 2 日星期六的報告中將 ImmunoPrecise Antibodies 的股票評級從 “賣出” 上調至 “持有”。根據 MarketBeat 的數據顯示，有兩位投資分析師對該股票給予了買入評級。目前，ImmunoPrecise Antibodies 的平均評級為 “買入”，平均目標價為$4.00。</p>
<p><strong>查看我們對 IPA 的最新股票分析</strong></p>
<h2>ImmunoPrecise Antibodies 的機構交易</h2>
<ul>
<li>這款香水熱潮贏家似乎要創下新高</li>
</ul>
<p>一家對沖基金最近增加了對 ImmunoPrecise Antibodies 股票的持股。根據該公司最近向證券交易委員會（SEC）提交的 13F 表格，XTX Topco Ltd 在第二季度將其在 ImmunoPrecise Antibodies Ltd.（納斯達克：IPA - 免費報告）的持股增加了 394.4%。該基金在此期間購買了 72897 股後，持有 91382 股該公司的股票。根據其最近向證券交易委員會（SEC）提交的文件，XTX Topco Ltd 持有的 ImmunoPrecise Antibodies 的股份約佔 0.20%，價值 97000 美元。對沖基金和其他機構投資者持有該公司 6.70% 的股份。</p>
<h2>ImmunoPrecise Antibodies 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>ImmunoPrecise Antibodies Ltd.及其子公司在加拿大及國際上作為生物治療研究和技術公司運營。它提供用於複雜蛋白質類別的 NonaVac DNA，包括 GPCRs 和離子通道；以及用於生成抗類抗體的陽性單克隆抗體 Rapid Prime，並生產針對構象表位的單克隆抗體。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 ImmunoPrecise Antibodies</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>聯合太平洋：為美國工業復興鋪軌</li>
<li>什麼是成長股及其投資</li>
<li>TransDigm 的優勢：從備件到高額利潤</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>Spire Global：小衞星，大買入評級和上漲空間</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資$1,000 在 ImmunoPrecise Antibodies 嗎？</h2>
<p>在你考慮 ImmunoPrecise Antibodies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 ImmunoPrecise Antibodies 並不在名單上。</p>
<p>雖然 ImmunoPrecise Antibodies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>ImmunoPrecise Antibodies（納斯達克代碼：IPA）將於 9 月 15 日發佈 2026 年第一季度財報，分析師預測每股虧損 0.04 美元，收入為 590 萬美元。該公司上個季度報告的每股虧損為 0.04 美元，收入為 506 萬美元。目前，ImmunoPrecise 的市值為 9668 萬美元，市盈率為-3.08。分析師維持 “買入” 評級，平均目標價為 4.00 美元。機構投資者持有該公司 6.70% 的股份</p>

<p>ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Monday, September 15th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $5.90 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Monday, September 15, 2025 at 10:30 AM ET.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies（納斯達克：IPA - 獲取免費報告）可能會在 2025 年 9 月 15 日星期一市場開盤前公佈其 2026 年第一季度的業績。分析師預計該公司將宣佈每股收益為（$0.04），季度收入為 590 萬美元。投資者可以訪問該公司即將發佈的 2026 年第一季度財報頁面，以獲取關於定於 2025 年 9 月 15 日東部時間上午 10:30 的電話會議的最新詳情。</p>
</div><ul>
<li>3 personal care stocks that smell like good earnings plays</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只個人護理股票，似乎是良好的收益投資機會</li>
</ul>
</div><p>ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies（納斯達克：IPA - 獲取免費報告）上一次公佈其財報是在 7 月 29 日星期二。該公司報告季度每股收益（EPS）為（$0.04），低於市場共識預期的（$0.02）$0.02。該季度的收入為 506 萬美元，而市場共識預期為 789 萬美元。ImmunoPrecise Antibodies 的淨利潤率為-122.10%，股本回報率為-40.62%。分析師平均預計 ImmunoPrecise Antibodies 在當前財年將發佈$0 的每股收益，並在下一個財年也將發佈$0 的每股收益。</p>
</div><h2>ImmunoPrecise Antibodies Trading Up 8.5%</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 股價上漲 8.5%</h2>
</div><p>IPA opened at $2.10 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.85 and a debt-to-equity ratio of 0.49. The firm has a market cap of $96.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.53. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $3.25. The stock has a fifty day moving average price of $1.98 and a 200-day moving average price of $1.03.</p>
<div class="lb-trans"><p>IPA 週一開盤價為$2.10。該公司的流動比率為 2.08，速動比率為 1.85，債務與股本比率為 0.49。該公司的市值為 9668 萬美元，市盈率為-3.08，貝塔值為 0.53。ImmunoPrecise Antibodies 的 12 個月最低價為$0.27，最高價為$3.25。該股票的 50 日移動平均價格為$1.98，200 日移動平均價格為$1.03。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>MarketBeat Week in Review – 07/31 - 08/04</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 07/31 - 08/04</li>
</ul>
</div><p>Separately, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, ImmunoPrecise Antibodies currently has an average rating of &#34;Buy&#34; and an average target price of $4.00.</p>
<div class="lb-trans"><p>另外，華爾街 Zen 在 8 月 2 日星期六的報告中將 ImmunoPrecise Antibodies 的股票評級從 “賣出” 上調至 “持有”。根據 MarketBeat 的數據顯示，有兩位投資分析師對該股票給予了買入評級。目前，ImmunoPrecise Antibodies 的平均評級為 “買入”，平均目標價為$4.00。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on IPA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 IPA 的最新股票分析</strong></p>
</div><h2>Institutional Trading of ImmunoPrecise Antibodies</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 的機構交易</h2>
</div><ul>
<li>Smells Like New Highs for This Fragrance Boom Winner</li>
</ul>
<div class="lb-trans"><ul>
<li>這款香水熱潮贏家似乎要創下新高</li>
</ul>
</div><p>A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. XTX Topco Ltd increased its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 394.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,382 shares of the company's stock after purchasing an additional 72,897 shares during the period. XTX Topco Ltd owned approximately 0.20% of ImmunoPrecise Antibodies worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.70% of the company's stock.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對 ImmunoPrecise Antibodies 股票的持股。根據該公司最近向證券交易委員會（SEC）提交的 13F 表格，XTX Topco Ltd 在第二季度將其在 ImmunoPrecise Antibodies Ltd.（納斯達克：IPA - 免費報告）的持股增加了 394.4%。該基金在此期間購買了 72897 股後，持有 91382 股該公司的股票。根據其最近向證券交易委員會（SEC）提交的文件，XTX Topco Ltd 持有的 ImmunoPrecise Antibodies 的股份約佔 0.20%，價值 97000 美元。對沖基金和其他機構投資者持有該公司 6.70% 的股份。</p>
</div><h2>ImmunoPrecise Antibodies Company Profile</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies Ltd.及其子公司在加拿大及國際上作為生物治療研究和技術公司運營。它提供用於複雜蛋白質類別的 NonaVac DNA，包括 GPCRs 和離子通道；以及用於生成抗類抗體的陽性單克隆抗體 Rapid Prime，並生產針對構象表位的單克隆抗體。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than ImmunoPrecise Antibodies</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Union Pacific: Laying the Tracks for America's Industrial Renewal</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>TransDigm’s Edge: From Spare Parts to Sky-High Profits</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Spire Global: Tiny Satellites, Big Buy Ratings and Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 ImmunoPrecise Antibodies</li>
<li>股票拆分，真的會影響投資者嗎？</li>
<li>聯合太平洋：為美國工業復興鋪軌</li>
<li>什麼是成長股及其投資</li>
<li>TransDigm 的優勢：從備件到高額利潤</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>Spire Global：小衞星，大買入評級和上漲空間</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IPA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ImmunoPrecise Antibodies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 ImmunoPrecise Antibodies 嗎？</h2>
</div><p>Before you consider ImmunoPrecise Antibodies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ImmunoPrecise Antibodies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 ImmunoPrecise Antibodies 並不在名單上。</p>
</div><p>While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ImmunoPrecise Antibodies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

ImmunoPrecise Antibodies (IPA) 將在週一公佈季度財報